advertisement
Ward CL 8
Showing records 1 to 8 | Display all abstracts from Ward CL70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Miller Ellis E
British Journal of Ophthalmology 2017; 101: 796-800
69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Harris A; Ward CL
Journal of Glaucoma 2016; 25: e826-e833
70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Berlin MS
British Journal of Ophthalmology 2017; 101: 796-800
69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Rowe-Rendleman CL
Journal of Glaucoma 2016; 25: e826-e833
70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Ward CL; Sharpe JA
British Journal of Ophthalmology 2017; 101: 796-800
69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Ouchi T; Wood A
Journal of Glaucoma 2016; 25: e826-e833
70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Jamil A; Harris A
British Journal of Ophthalmology 2017; 101: 796-800
69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Fujii A; Serle JB
Journal of Glaucoma 2016; 25: e826-e833
